Singapore markets closed
  • Straits Times Index

    -6.23 (-0.20%)
  • S&P 500

    +26.83 (+0.59%)
  • Dow

    +294.60 (+0.82%)
  • Nasdaq

    +78.83 (+0.55%)
  • Bitcoin USD

    +2,468.84 (+6.27%)
  • CMC Crypto 200

    +71.00 (+8.97%)
  • FTSE 100

    -33.15 (-0.44%)
  • Gold

    -1.20 (-0.06%)
  • Crude Oil

    -0.57 (-0.77%)
  • 10-Yr Bond

    0.0000 (0.00%)
  • Nikkei

    -200.24 (-0.60%)
  • Hang Seng

    -184.25 (-1.09%)
  • FTSE Bursa Malaysia

    -5.36 (-0.37%)
  • Jakarta Composite Index

    +33.69 (+0.48%)
  • PSE Index

    +39.19 (+0.63%)

The Zacks Analyst Blog Highlights AstraZeneca, NextEra Energy, The Boeing, The PNC Financial Services Group and Centene

For Immediate Release

Chicago, IL – January 24, 2023 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AstraZeneca PLC AZN, NextEra Energy, Inc. NEE, The Boeing Co. BA, The PNC Financial Services Group, Inc. PNC and Centene Corp. CNC

Here are highlights from Monday’s Analyst Blog:

Top Analyst Reports for AstraZeneca, NextEra and Boeing

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AstraZeneca PLC, NextEra Energy, Inc. and The Boeing Co. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today's research reports here >>>

AstraZeneca shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+21.4% vs. +16.2%). The company's key drugs, mainly cancer medicines, Lynparza, Tagrisso and Imfinzi should keep driving revenues. Its pipeline is strong with several phase III data readouts lined up.

AstraZeneca has also been engaged in external acquisitions and strategic collaborations to boost its pipeline while investing in geographic areas of high growth like emerging markets. The Alexion buyout strengthens its immunology franchise, adding several drugs that are boosting its top line.

However, AstraZeneca's diabetes franchise faces stiff competition while pricing pressure hurts sales in the respiratory unit. Sales are slowing down in its key market, China. Estimate movement is mixed ahead of the Q4 earnings release. The company has a positive record of earnings surprises in the recent quarters.

(You can read the full research report on AstraZeneca here >>>)

NextEra Energy shares have outperformed the Zacks Utility - Electric Power industry over the past six months (+1.0% vs. -2.3%). The company continues to expand its operations through the efficient execution of organic projects and acquisitions. The company currently has many renewable projects in its backlog and their completion will ensure reduced emissions.

The merger of Gulf Power and FPL strengthens NextEra's position in Florida.FPL's customer base is expanding as Florida's economy improves and its services become more reliable. Expanding customer base continues to boost demand for its services. NextEra has ample liquidity to meet its near-term debt obligations.

However, the nature of its business is subject to complex federal, state and other regulations. Risk in operating nuclear units, unfavorable weather conditions and an increase in supply costs adversely impact earnings.

(You can read the full research report on NextEra Energy here >>>)

Shares of Boeing have outperformed the Zacks Aerospace - Defense industry over the past year (+1.2% vs. -8.8%). The company remains the largest aircraft manufacturer in the United States in terms of revenue, orders and deliveries. Lately, the company has been witnessing solid recovery in its commercial business, particularly in domestic air traffic.

The outlook for its defense business also remains optimistic, buoyed by solid U.S. budgetary amendments. It also holds a strong solvency position in the near term.  However, the 737 MAX is yet to return to service in China thus impacting its expectation of delivery timing and future gradual production rate increases.

Boeing continues to face production quality issues for its 787 program. Boeing incurred cumulative abnormal costs of $1.4 billion through September 2022 and expects to incur nearly $2 billion for the 787 program.

(You can read the full research report on Boeing Company here >>>)

Other noteworthy reports we are featuring today include The PNC Financial Services Group, Inc. and Centene Corp.

Why Haven't You Looked at Zacks' Top Stocks?

Our 5 best-performing strategies have blown away the S&P's impressive +28.8% gain in 2021. Amazingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today you can access their live picks without cost or obligation.

See Stocks Free >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339               

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

The Boeing Company (BA) : Free Stock Analysis Report

NextEra Energy, Inc. (NEE) : Free Stock Analysis Report

AstraZeneca PLC (AZN) : Free Stock Analysis Report

The PNC Financial Services Group, Inc (PNC) : Free Stock Analysis Report

Centene Corporation (CNC) : Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research